Figures

Fig. 1




Fig. 2




Fig. 3



2mM Pirfenidone + 10nM COMPOUND C
αSMA expression
110
100
90
80
70
60
50
40
30
20
10
0
vehicle
TGFß
+Pirf 2mM
+CPD C 10nM
+combo
expected combo inhibition
42%
measured combo inhibition
80%

Fig. 4




2mM Pirfenidone + 10nM COMPOUND D
αSMA expression
110
100
90
80
70
60
50
40
30
20
10
0
vehicle
TGFß
+Pirf 2mM
+CPD D 10nM
+combo
expected combo inhibition
45%
measured combo inhibition
88%

Fig. 5



	IC50
Pirfenidone	3
+10nM COMPOUND A	2
+100nM COMPOUND A	2
+1000nM COMPOUND A	1

Fig. 6




Fig. 7




1µM Nintedanib + 10nM COMPOUND B
αSMA expression
100
90
80
70
60
50
40
30
20
10
0
vehicle
TGFß
+Nint 1µM
+CPD B 10nM
+combo
expected combo inhibition
≈
measured combo inhibition
65%

Fig. 8


1µM Nintedanib + 10nM COMPOUND C
αSMA expression
110
100
90
80
70
60
50
40
30
20
10
0
vehicle
TGFß
+Nint 1µM
+CPD C 10nM
+combo
expected combo inhibition
34%
measured combo inhibition
62%